hero inpact

Tested. Trusted. Market-leading drug-coated balloon


75% of patients treated with IN.PACT™ Admiral™ Paclitaxel-coated
PTA Balloon Catheter remain reintervention-free at 5 years1
Contact a representative
Alert Indications, Safety, and Warnings

Long-term outcomes

IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter continues to demonstrate long-term clinical outcomes, even in patients considered to be at high risk of restenosis and repeat interventions.

 

Freedom from CD-TLR through 5 years:

  • 74.5% IN.PACT SFA Trial1
  • 58.0% IN.PACT Global ISR Cohort2
  • 67.3% IN.PACT Global Long Lesion Cohort2
  • 69.8% IN.PACT Global CTO Cohort2
IN.PACTTM AdmiralTM Trials

BACK TO TOP

IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter has the:

View the data
dcb

Proven formulation

The IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter features a proprietary FreePac™ coating solution that allows for the release of drug into the tissue through the restenotic window.
View product data

Duration of paclitaxel in tissue

IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter provides 180 days of drug in tissue.§3
pta ballon

BACK TO TOP

We have extended our DCB range

Introducing new longer lengths to our IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter range, to give you more options for treatment of longer, complex lesions. 
Clinical performance
  • Highest primary patency7 91.1%8
  • Mean Lesion length 26cm
See size options
View product details
dcb-range

Impacting patient care

Watch Dr. Ehrin Armstrong speak about the benefits and clinical evidence to support IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter as his DCB of choice.
More information (see more) Less information (see less)

Meet Robert Canterbury, who was diagnosed with peripheral artery disease (PAD), and see how IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheterhelped get him back on his feet.
More information (see more) Less information (see less)

BACK TO TOP

Additional resources

One proven formulation, two platforms for SFA treatment.

With 0.035” and 0.018” guidewire compatibility.

More information

Related resources



Lifeline cardiovascular technical support

Worldwide technical support - 24/7

+ 1 763-514-4000

rs.cstechsupport@medtronic.com

BACK TO TOP

Contact a representative

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

BACK TO TOP

*Third-party brands are trademarks of their respective owners.
**Based on sales units sold since commercialization. Units sold divided by units per procedure.
† Primary patency not assessed after three years.
‡ Data on file UC202013694cEE at Medtronic. https://europe.medtronic.com/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/pvh/going-long-dcb/DCB_landscape_revision.pdf
§ Data comes from different individual studies and may differ in a head-to-head comparison, and therefore may not be predictive of clinical results.

References

1

Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702.

2

Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA, 2021.

3

FDA. PMA P140010: Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p140010(opens new window). Accessed May 10, 2022.

4

FDA. PMA P190019: FDA Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190019(opens new window). Accessed May 10, 2022.

5

Virmani R. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv. January 1, 2014;83(1):132-140.

6

FDA. PMA P160049: FDA summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160049(opens new window). Accessed May 10, 2022.

7

Based on clinical data for drug-coated balloons indicated to treat long SFA lesions (>180 mm): compared to Lutonix™* IFU BAW1387400r3. Per Stellarex™* IFU P011966-B, Stellarex is not indicated to treat lesions longer than 180 mm. Definitions of patency and lesion length may vary for different studies.

8

The IN.PACT Global Study Long Lesion Imaging Cohort D. Scheinert Circulation 2018.

9

Granada JF, Stenoien M, Buszman PP, et al. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart. August 6, 2014;1(1):e000117.